The role of mesenchymal stem cells in haemopoiesis

Dazzi, Francesco; Ramasamy, Rajesh; Glennie, Sarah; Jones, Simon P.; Roberts, Irene

doi:10.1016/j.blre.2005.11.002

Cited by 305 publications

(229 citation statements)

References 114 publications

Supporting

Mentioning

204

Contrasting

Unclassified

Order By: Relevance

“…5 MSCs can migrate to sites of tissue damage, 6,7 where they are activated by inflammatory cytokines (such as IFN-c) and several chemokines, which can recruit or suppress lymphocytes. [8][9][10][11] Interleukin-1b (IL-1b) is an important inflammatory factor that is expressed abundantly during the active phase of UC. [12][13][14] The UC mice induced by DSS treatment exhibit many symptoms similar to human UC, such as diarrhea, bloody feces, body weight loss, mucosal ulceration and shortening of the large intestine.…”

Section: Introductionmentioning

confidence: 99%

Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis

et al. 2012

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have been used experimentally for treating inflammatory disorders, partly due to their immunosuppressive properties. Although interleukin-1b (IL-1b) is one of the most important inflammatory mediators, growing evidence indicates that IL-1b signaling elicits the immunosuppressive properties of MSCs. However, it remains unclear how IL-1b signaling accomplishes this activity. Here, we focus on the therapeutic efficacy of IL-1b-primed MSCs in the dextran sulfate sodium (DSS)-induced colitis model, in addition to the underlining mechanisms. We first found that IL-1b-primed MSCs, without any observable phenotype change in vitro, significantly attenuated the development of DSS-induced murine colitis. Moreover, IL-1b-primed MSCs modulated the balance of immune cells in the spleen and the mesenteric lymph nodes (MLNs) through elevating cyclooxygenase-2 (COX-2), IL-6 and IL-8 expression and influencing the polarization of peritoneal macrophages. Importantly, IL-1b-primed MSCs possessed an enhanced ability to migrate to the inflammatory site of the gut via upregulation of chemokine receptor type 4 (CXCR4) expression. In summary, IL-1b-primed MSCs have improved efficacy in treating DSS-induced colitis, which at least partly depends on their increased immunosuppressive capacities and enhanced migration ability.

show abstract

Section: Introductionmentioning

confidence: 99%

Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…1,2 They are progenitors of bone marrow stroma and thus play a crucial role in supporting hematopoiesis 3,4 by providing hematopoietic progenitors, the necessary cytokines and cell contact-mediated signals to self-renew and/or differentiate. 5 It has also been widely demonstrated that MSC exhibit a potent immunosuppressive activity, which targets virtually all types of immune cells of both lymphoid and myeloid lineage. There is evidence that such a broad activity results from a selective inhibition of cell cycle at early stages of cell commitment (G 0 /G 1 ) 6 and whereas cell proliferation is vigorously reduced, most of immune effectors functions are substantially preserved.…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth

Ramasamy¹,

et al. 2006

View full text Add to dashboard Cite

Mesenchymal stem cells (MSC) have received much attention in the field of hematopoietic stem cell transplantation because not only do they support hematopoiesis but also exhibit a profound immunosuppressive activity that can be exploited to prevent undesired alloreactivity. We have previously shown that their immunosuppressive activity is mainly exerted at the level of T-cell proliferation. Here, we show that MSC exhibit a similar antiproliferative activity on tumor cells of hematopoietic and non hematopoietic origin. In vitro, MSC produced the transient arrest of tumor cells in the G 1 phase of cell cycle; this was accompanied by a reduction in the apoptotic rate even when survival factors were limiting. However, when tumor cells were injected into non-obese diabetic-severe combined immunodeficient mice in conjunction with MSC, their growth was much faster as compared to the group receiving only tumor cells. To explain the discrepancy between the in vitro and in vivo behavior, we suggest that MSC have the ability to form a cancer stem cell niche in which tumor cells can preserve the potential to proliferate and sustain the malignant process. We conclude that the clinical use of MSC in conditions in which a malignant disease is involved should be handled with extreme caution.

show abstract

“…The level of hepatocyte growth factor expression has been shown to be much higher in placenta-derived mesenchymal stem cells, compared to adult mesenchymal stem cells (Zhu et al 2014). Mesenchymal stem cells can produce a large number of interleukin (IL)-6, IL-7, IL-11, stromal cell-derived factor, leukemia inhibitor factor, stem cell factor, and Flt3 ligand, which are several essential hematopoietic growth factors (Grebnev et al 2015;Chaudhary et al 1992;Tolar et al 2010;Zhang et al 2011;Dazzi et al 2006;Yañez et al 2006;Sorrentino et al 2008). IL-6 can activate the immune and hematopoietic systems (Lazzari et al 2001).…”

Section: Discussionmentioning

confidence: 99%

Multiplacenta derived stem cell/cytokine treatment increases survival time in a mouse model with radiation-induced bone marrow damage

Wei

Yan

et al. 2016

Cytotechnology

View full text Add to dashboard Cite

Nuclear Warfare and nuclear leakage can result in a large number of patients with radiationinduced bone marrow damage. Based on the fact that hematopoietic stem cells and hematopoietic growth factors are characterized as a novel strategy for therapy, the aim of this study was to explore a safe and routine stem cell/cytokine therapeutic strategy. Allogeneic multiplacenta derived hematopoietic and mesenchymal stem cells/cytokines were intraperitoneally injected into a moderate dose of total body irradiation-induced mouse bone marrow damage model a single time. Then, the mouse posttransplantation survival time, peripheral blood hemoglobin count, bone marrow architecture, and donor cell engraftment were assessed. Each mouse that received placenta-derived stem cells exhibited positive donor hematopoietic and mesenchymal stem cell engraftment both in the bone marrow and peripheral blood after transplantation. The peripheral blood hemoglobin count and survival time were greater in the group with the combined treatment of multiplacenta-derived stem cells and cytokines, compared with model-only controls (both P \ 0.001). The blood smear mesenchymal/hematopoietic stem cell count was significantly higher in the combined treatment group than in the mice treated only with placenta-derived cells (28.08 ± 5.824 vs. 20.40 ± 5.989, P \ 0.001; 7.74 ± 2.153 vs. 4.23 ± 1.608, P \ 0.001, respectively). However, there was no marked change on the bone marrow pathology of any of the experimental mice after the transplantation. These results indicate that for radiation-induced bone marrow damage treatment,

show abstract

The role of mesenchymal stem cells in haemopoiesis

Cited by 305 publications

References 114 publications

Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis

Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis

Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth

Multiplacenta derived stem cell/cytokine treatment increases survival time in a mouse model with radiation-induced bone marrow damage

Contact Info

Product

Resources

About